Advertisement

Response to ‘considerations regarding a network meta-analysis of targeted therapies for BRAF mutant unresectable or metastatic melanoma’

Published:October 21, 2022DOI:https://doi.org/10.1016/j.ctrv.2022.102478
      The considerations of Dr Rizzo on the network meta-analysis (NMA) entitled ‘Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma: Results from a systematic literature review and a network meta-analysis’ [
      • Corrie P.
      • Meyer N.
      • Berardi R.
      • Guidoboni M.
      • Schlueter M.
      • Kolovos S.
      • et al.
      Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma: Results from a systematic literature review and a network meta-analysis.
      ], have been reviewed in detail. Dr Rizzo briefly summarised the study and acknowledged the rigorous methodological approach applied, but at the same time expressed some concerns about the study limitations.
      To read this article in full you will need to make a payment
      ESMO Member Login
      Login with your ESMO username and password.
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Purchase one-time access:

      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Corrie P.
        • Meyer N.
        • Berardi R.
        • Guidoboni M.
        • Schlueter M.
        • Kolovos S.
        • et al.
        Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma: Results from a systematic literature review and a network meta-analysis.
        Cancer Treat Rev. 2022; 110: 102463
        • Rouse B.
        • Chaimani A.
        • Li T.
        Network meta-analysis: an introduction for clinicians.
        Int Emerg Med. 2017; 12: 103-111
      1. Mills EJ, Thorlund K, Ioannidis JP. Demystifying trial networks and network meta-analysis. Bmj. 2013;346.

      2. Centre for Reviews and Dissemination TUoYOg. <https://www.york.ac.uk/crd/guidance/>.

        • Lunn D.J.
        • Thomas A.
        • Best N.
        • Spiegelhalter D.
        WinBUGS-a Bayesian modelling framework: concepts, structure, and extensibility.
        Stat Comput. 2000; 10: 325-337
      3. Dias S, Welton NJ, Sutton AJ, Ades A. A generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials: National Institute for Health and Care Excellence (NICE) London; 2014.

      4. Hoaglin DC, Hawkins N, Jansen JP, Scott DA, Itzler R, Cappelleri JC, et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR task force on indirect treatment comparisons good research practices: part 2. Value in health. 2011;14(4):429-37.